OncoMatch/Clinical Trials/NCT07673861
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
Is NCT07673861 recruiting? Yes, currently enrolling (Jul 2026). This NA trial studies non-drug interventions for non small cell lung cancer.
ctDNA stands for circulating tumour DNA. As ctDNA is released by tumour cells into the blood stream, taking a blood sample and analysing it for ctDNA, can provide a lot of useful information about a patient's cancer. In certain situations, ctDNA can be used to screen for or detect cancer early, to aid clinical decisions about which treatment to give a patient, to provide information about if a cancer has become resistant to treatment, or provide information about how much cancer may be left after treatment (residual disease). The aim of this trial is to establish the clinical utility of implementing ctDNA testing in cancer patients with a view to enhance the delivery of personalised care within the National Health Service in the United Kingdom (UK). One hundred patients will be recruited, with 20 from each of the following cancer types: * Non-small cell lung cancer * Gastrointestinal stromal tumours * Colorectal cancer * Biliary tract cancer * Ovarian cancer. Patients must be aged 18 or over, must have had progressive disease whilst receiving anti-cancer treatment, and must be being treated at The Royal Marsden. Patients will have a blood sample taken and analysed using the Marsden360 ctDNA test. The results of the test will be looked at by The Royal Marsden Genomic Tissue Advisory Board (GTAB), and for each individual patient, the GTAB will determine if having a ctDNA test helped to personalise their care by: * Aiding the identification of a genomically-matched standard of care therapy * Aiding the identification of a genomically-matched clinical trial (based in the UK) * Offering additional prognostic information not otherwise available through standard of care testing * Negating the need for a tissue biopsy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Gastrointestinal Stromal Tumor
Colorectal Cancer
Cholangiocarcinoma
Ovarian Cancer
Biomarker criteria
Required: EGFR oncogenic driver
Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR/ALK/ROS1/RET/MET/BRAF/NTRK/HER2/KRAS)
Required: ALK oncogenic driver
Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR/ALK/ROS1/RET/MET/BRAF/NTRK/HER2/KRAS)
Required: ROS1 oncogenic driver
Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR/ALK/ROS1/RET/MET/BRAF/NTRK/HER2/KRAS)
Required: RET oncogenic driver
Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR/ALK/ROS1/RET/MET/BRAF/NTRK/HER2/KRAS)
Required: MET oncogenic driver
Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR/ALK/ROS1/RET/MET/BRAF/NTRK/HER2/KRAS)
Required: BRAF oncogenic driver
Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR/ALK/ROS1/RET/MET/BRAF/NTRK/HER2/KRAS)
Required: NTRK1 oncogenic driver
Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR/ALK/ROS1/RET/MET/BRAF/NTRK/HER2/KRAS)
Required: NTRK2 oncogenic driver
Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR/ALK/ROS1/RET/MET/BRAF/NTRK/HER2/KRAS)
Required: NTRK3 oncogenic driver
Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR/ALK/ROS1/RET/MET/BRAF/NTRK/HER2/KRAS)
Required: KRAS oncogenic driver
Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR/ALK/ROS1/RET/MET/BRAF/NTRK/HER2/KRAS)
Required: HRR pathogenic variant
Locally advanced/metastatic gastrointestinal stromal tumour (GIST), AND progressive disease on targeted therapy
Required: KRAS wild-type
Metastatic colorectal cancer, left sided, RAS wild type
Required: NRAS wild-type
Metastatic colorectal cancer, left sided, RAS wild type
Required: IDH1 mutation
IDH1 mutation
Required: FGFR2 fusion
FGFR2 fusion or rearrangement
Required: FGFR2 rearrangement
FGFR2 fusion or rearrangement
Required: NTRK1 fusion
NTRK fusion
Required: NTRK2 fusion
NTRK fusion
Required: NTRK3 fusion
NTRK fusion
Required: BRAF v600e
BRAF V600E mutation
Required: MLH1 loss
MMR deficiency [dMMR]
Required: MSH2 loss
MMR deficiency [dMMR]
Required: MSH6 loss
MMR deficiency [dMMR]
Required: PMS2 loss
MMR deficiency [dMMR]
Required: BRCA1 mutation
Known BRCA status
Required: BRCA2 mutation
Known BRCA status
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: targeted therapy — NSCLC
Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent
Must have received: targeted therapy — GIST
Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent
Must have received: systemic anti-cancer therapy with anti-EGFR agent (cetuximab) — CRC, HER2 negative or unknown
progressive disease on systemic anti-cancer therapy (SACT) with an anti-EGFR agent (e.g. cetuximab) within the 6 weeks prior to consent
Must have received: systemic anti-cancer therapy +/- anti-EGFR agent — CRC, HER2 positive
progressive disease on first line systemic anti-cancer therapy (SACT) +/- an anti-EGFR agent within the 6 weeks prior to consent
Must have received: targeted therapy — BTC
Progressive disease on targeted therapy (any line) demonstrated within the 6 weeks prior to consent
Must have received: PARP inhibitor — Ovarian cancer, following platinum-based therapy in 1st line maintenance
Progressive disease on a PARP-inhibitor (with or without bevacizumab) following platinum-based therapy in the 1st line maintenance setting, within the 6 weeks prior to consent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07673861 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received targeted therapy and targeted therapy.
Does this trial require EGFR?
Yes, EGFR oncogenic driver is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK oncogenic driver is a required biomarker for enrollment.
Does this trial require ROS1?
Yes, ROS1 oncogenic driver is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify